Engraftment Kinetics in Children After Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation (RIC-HSCT)  by Schneiderman, J. et al.
Poster Session I S2612SE6%.These results suggest that replacement of rabbit ATG with
Alemtuzumab may improve engraftment and decrease GVHD rates
without resulting in delays in immune reconstitution.293
CYSTATIN C IS A MORE SENSITIVE ESTIMATE OF KIDNEY FUNCTION
THAN CREATININE IN PEDIATRIC AUTOLOGOUS BONE MARROW
TRANSPLANTATION
Laskin, B.L.1, Goebel, J.1, Bissler, J.J.1, Khoury, J.C.2, Davies, S.M.3,
Jodele, S.3 1Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH; 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;
3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Overview: Accurate assessment of kidney function is essential in the
care of bone marrow transplant (BMT) patients. Both cystatin C,
a protease inhibitor produced by all nucleated cells and measured
in a single blood sample, and creatinine are used to estimate kidney
function (glomerular filtration rate, GFR).While creatinine is influ-
enced by muscle mass, cystatin C is potentially modified by cortico-
steroids, thyroid function, and the white blood cell count (WBC).
The literature is conflicting on the validity of cystatin C measure-
ments in BMT and oncology patients, and the effect of leukopenia
is understudied. We hypothesize that cystatin C is a more sensitive
estimate of kidney function in BMT patients, while controlling for
the WBC.
Methods:We retrospectively compared cystatin C to creatinine for
predicting nuclear GFR (technetium-99m-DTPA; nucGFR) in pe-
diatric recipients of autologous BMTs. General linear mixed models
were used to calculate regression and intra-class correlation coeffi-
cients (ICC, ranging from 0-1 with higher values indicating less var-
iation/greater reliability between the estimates). Prediction models
used cystatin C GFR5 [77.24*cys21.2623] (cysGFR), with and with-
out WBC, and Schwartz GFR 5 [0.413*height (cm)/creatinine]
(schGFR).
Results: 12 patients (median age 3.5 yrs, range 2-10 yrs) underwent
29 tandem BMTs (median 2 BMTs/patient, range 1-4) for medullo-
blastoma (n5 7), neuroblastoma (n5 4), and atypical teratoid rhab-
doid tumor (n 5 1). All patients except 1 had normal thyroid
function. 3 patients received steroids (2 stress dosing and 1 high-
dose for veno-occlusive disease of the liver). GFRs (mean6std error)
in ml/min/1.73m2 (normal . 90) were 142.069.0 (nuc), 136.566.2
(cys), and 132.165.1 (sch). ICCs were 0.54 for nucGFR versus
cysGFR and 0.26 for nucGFR versus schGFR. Furthermore, the
Pearson correlation coefficient was much higher for cysGFR (0.80,
p\0.001) than for schGFR (0.22, p5 0.36) compared to nucGFR.
Regression coefficients and the 95% confidence intervals (CI) for the
prediction models are shown in the table.
Conclusions: Cystatin C was a statistically significant predictor of
nucGFR while creatinine was not. WBC was of borderline signifi-
cance in prediction of nucGFR using cysGFR. To maximize clinical
utility, future research will confirm these findings by accounting for
additional confounders in a larger group of patients and a wider
range of GFR.
Independent
predictors in
model for nucGFR b regression coefficients [95% CI]cysGFR* 0.96 [0.77, 1.14]
cysGFR* & WBC 1.08 [0.94, 1.23] & 0.67 [-1.02, 2.36]
schGFR 0.17 [-0.072, 0.41]*statistically significant (p<0.05)294
A MULTIDISCIPLINARY APPROACH TO ADHERENCE IMPROVEMENT US-
ING EDUCATION AND MEDICATION BOXES FOR ADOLESCENTS AND
YOUNG ADULTS WHO HAVE UNDERGONE ALLOGENEIC HEMATO-
POEITIC STEM CELL TRANSPLANTATION
McBride, J., Shinkle, M. Children’s Memorial Hospital, Chicago, IL
Achieving adherence to immunosuppressive medications in the
adolescent population of post allogeneic stem cell transplant canbe challenging. Literature has documented consistently a link be-
tween regimen complexity and adherence rates. Non-adherence
can put patients at increase risk of uncontrolled graft versus host dis-
ease. While there is literature describing adolescent barriers to ad-
herence and their attitudes regarding medications, no studies have
evaluated the use of medication boxes in combination with a multi-
disciplinary patient education on adherence. A pilot study was un-
dertaken to see if use of a medication box combined with a 15
minute discussion with a pharmacist and social worker about barriers
to adherence, the importance of medication adherence, and how to
use the box will improve adherence in adolescent post allogeneic
stem cell transplant patients. Medication boxes were initially filled
by a health care professional on the patients’ clinic day. Pill counts
were used to assess adherence rates. Patients completed surveys
about their perception on their medications prior to, during, and af-
ter the intervention. 11 patients consented to study to date (ages 13-
25); 1 patient withdrew, 1 patient died prior to start of the study, and
1 patient has yet to start. During the active medication box phase of
the study, patient’s adherence rates ranged from 57-100% with all
but one patient having an adherence rate . 80%. When study par-
ticipants where asked if they do a good job caring for themselves 7
out of 9 responded positively (somewhat to strong agreement); al-
though, 5 out of 8 reported missed doses at least once during the
study duration. Of note, 6 out of 9 participants at some point during
the study duration reported agreement or neutrality to the statement
‘I don’t think I need my medication’ and 8 out of 9 patients reported
agreement or neutrality to the statement ‘My doctors want me to
take too many medications’. These findings are of interest because
they may reflect unique characteristics of adolescent development,
how their views on their health and medications may change
throughout a treatment course, whichmay have direct effect onmed-
ication adherence. This pilot study supports the use of medication
boxes for adolescents post allogeneic stem cell transplantation. Fur-
ther studies need to be done to assess what patients would most ben-
efit by having their medication box filled for them.295
ENGRAFTMENT KINETICS IN CHILDREN AFTER REDUCED INTENSITY
CONDITIONING HEMATOPOIETIC STEM CELL TRANSPLANTATION (RIC-
HSCT)
Schneiderman, J., Kletzel, M., Chaudhury, S., Duerst, R., Tse, W.T.
Northwestern University Feinberg School of Medicine, Children’s Memo-
rial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
The kinetics of stem cell engraftment following RIC-HSCT are
different from that of myeloablative transplant; previous analyses
are limited to adults. Between 2003 and 2010, we performed RIC-
HSCT in 88 children with malignant (n 5 40) or non-malignant
(48) diseases; none had prior HSCT. Patient characteristics are
shown in Table 1. Post-HSCT, total white cells donor chimerism
was monitored serially by variable number tandem repeat analysis
once the peripheral white blood cell count exceeded 1,000 cells/
ml. The cumulative incidence of patients reaching 50% and 90%do-
nor chimerism by +20/40/60 days post-HSCT was 67/85/86% and
41/68/72%, respectively. Eight patients (8/88 5 9%) had primary
graft failure, with chimerism never reaching 20%. Sixty-six patients
(75%) have peak chimerism over 90%, whereas 14 patients (16%)
have peak chimerism between 20-90%. Among those engrafted (n
5 82), chimerism in 57 patients (70%) was durable and did not de-
cline with time, but in 25 patients (30%), there was a drop in chime-
rism of . 10% between two consecutive measurements. Median
time of chimerism drop was +60 days post-HSCT (range 17-193
days). Seven patients (7/82 5 8%) experienced relapse of leukemia
soon after the drop was detected, 12 patients (15%) had stabilization
or improvement of chimerism after withdrawal of immunosuppres-
sion and/or donor lymphocyte infusion (DLI), and 6 patients (7%)
had no recovery despite immune manipulation, resulting in second-
ary graft failure. There is no correlation between the magnitude of
chimerism drop and the response to immune manipulation. There
were differences in engraftment kinetics among patients with malig-
nant or non-malignant diseases. In the malignant group, the cumu-
lative incidence of 90% donor chimerism at +100 days was 87.5%,
and at one year, the percentage of patients with full or mixed chime-
rism was 90% and 10%, respectively. By contrast, in the non-
S262 Poster Session Imalignant group, the cumulative incidence of 90% donor chimerism
at +100 days was only 64.6%, and the percentage of full or mixed chi-
merism at one year was 76% and 24%. Our data show that while
RIC-HSCT leads to durable and full donor chimerism in the major-
ity of patients, some experience engraftment instability, which could
respond to timely intervention with withdrawal of immune suppres-
sion and/or DLI. Frequent and long-term monitoring of donor chi-
merism would offer the opportunity to positively impact the clinical
course of these patients.
Table 1. Patient Characteristics (n588)Median Age7
57.3 years
(20 days - 21 years)M/F 47/41
Diagnoses
Malignant 40
ALL/AML/MDS 13/4/7
CML 5
Relapsed HD 3
Other 8
Non-malignant 48
SCID 13
SAA 7
Other 28
HPC Source
Matched Sibling/Related 34
MUD/MM Related 22
MMUD 32
PBSC/Marrow/Cord 74/2/12
Median Cell Dose
CD 34+/Kg  10^6 (0.12 - 37.5)
MNC/Kg  10^8 (0.27 - 9.5)
Conditioning Regimen
Fludarabine/Busulfan/ATG 57
Fludarabine/Busulfan/ECP 19
Fludarabine/Busulfan 5
Other fludarabine 7296
CLINICAL RELEVANCE OF SERIAL CHIMERISM ANALYSIS AFTER ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
WITH NON-MALIGNANT DISEASES
Park, M., Koh, K.N., Kim, B.E., Choi, E.S., Shin, H., Im, H.J., Seo, J.J.
Asan Medical Center Children’s Hospital, University of Ulsan College of
Medicine, Seoul, Korea
Background: In allogeneic hematopoietic stem cell transplantation
(HSCT), the effect of chimerism often remains unclear andmay have
different implications in various diseases. We performed retrospec-
tive study to evaluate chimerism status and transplant outcome in
children with non-malignant diseases.
Patients & Methods: Between September 1999 and January 2010
we analyzed the data of 42 transplants performed in 40 children
with nonmalignant diseases. Short tandem repeat polymerase chain
reaction (STR-PCR) was used to evaluate chimerism. Mixed chime-
rism (MC) was defined as . 1% recipient cells.
Results:MCwas detected in 17 (40%) transplants. Of these 17 cases,
8 developed decreasingMC, 6 persisted with low-proportions of au-
tologous cells below 30% (stable MC) and 3 showed $ 30% recipi-
ent signals in two consecutive samples (high MC). Among 4 graft
failures, one showed autologous recovery. The 2 patients with graft
failure received the second transplant, of whom one is alive in remis-
sion. The remaining one received donor lymphocyte infusion (DLI)
due to the high MC, which subsequently resulted in further increase
of autologous cells. The incidence of MC was not different statisti-
cally between reduced intensity conditioning andmyeloablative con-
ditioning. The probabilities of achieving complete donor chimerism
(CC) at 1, 3, 6 and 12 months after HSCT were 70.0%, 68.3%,
75.7% and 78.8%, respectively. Overall probability of grade II–IV
acute GVHD was significantly higher in CC group compared to
the MC group (57.1% vs. 11.8%, p 5 0.006). High MC was associ-
ated with graft failure (p 5 0.004). At a median follow-up of 36
months, the 3-year overall survival and event-free survival after
HSCT for non-malignant diseases in children were 90.0% and87.2%, respectively. There was no significant survival difference be-
tween CC and MC. Patients with high MC showed inferior survival
rate compared to the patients with stable or decreasing MC (33.3 vs.
92.3%, p 5 0.014).
Conclusions: In this study, overall incidence of MC was 40% after
transplantation for non-malignant diseases.MCmay indicate a toler-
ant state in transplanted individuals with a decreased incidence of
acute GVHD. However, high MC was at risk of graft failure and
also associated with lower survival rate. Sequential chimeric status
could give important information on post-transplant course after
HSCT for non-malignant diseases.297
FOLINIC ACID RESCUE INCREASES ABILITY TO DELIVER FULL COURSE OF
METHOTREXATE GVHD PROPHYLAXIS FOR PEDIATRIC HSCT RECIPI-
ENTS
Hudspeth, M., Heath, T., Chiuzan, C., Garrett-Mayer, E., Nista, E.,
Burton, L., Ragucci, D. Medical University of South Carolina, Charleston,
SC
Background: Cyclosporine and short-course MTX are commonly
used for GVHD prophylaxis in pediatric BMT. Day 11 MTX has
been administered to\ 75 % of patients in adult studies due to se-
vere mucositis or organ dysfunction. Omission of day 11 MTX is as-
sociated with an increased risk of GVHD. Folinic acid may
ameliorate MTX toxicity.
Methods:We conducted a retrospective chart review of all pediatric
patients from January 2000- July 2010 who received cyclosporine
and short course MTX for GVHD prophylaxis. One patient was ex-
cluded formissing records. Patients prior to July 2007 did not receive
folinic acid (N 5 18). All patients thereafter received folinic acid 10
mg/m2 IV 12 hours after each MTX dose (N5 29). Logistic regres-
sion was used to estimate the ORmeasuring the association between
folinic acid use and receipt of day 11MTX, adjusting for preparative
regimen, graft source, and disease status at BMT. Kaplan-Meier sur-
vival curves with a log-rank test were used to determine relapse-free
survival. Statistical significance was accepted at p\ 0.05.
Results: Patients who received folinic acid rescue were significantly
more likely to receive day 11MTX.(OR 10.42, 95%CI 1.21-262.27)
However, there was no significant difference inGrade III-IVGVHD
between the patients who received folinic acid rescue and those who
did not. (OR 1.15, 95% CI 0.08-18.14). Folinic acid rescue did not
impact relapse-free survival (P 5 0.82).
Conclusion:Although folinic acid rescue increased the likelihood of
receiving the day 11 MTX, this did not translate into a reduction of
Grade III-IV GVHD. However, there was also no difference in re-
lapse-free survival to suggest a deleterious effect on disease control,
which has been cited as a concern by some groups. Increased likeli-
hood of receiving day 11MTX does suggest that folinic acid amelio-
rates MTX toxicity, such as severe mucositis. Folinic acid rescue for
short course MTX should be studied in a prospective, randomized
fashion.298
DIGITAL MULTIPLEXED QUANTIFICATION OF BOTH T-CELL RECEPTOR
b-CHAIN AND a-CHAIN DIVERSITY IN T CELLS USING THE NANOSTRING
NCOUNTER ASSAY SYSTEM
Maiti, S.N.1, Zhang, M.2, Bernatchez, C.2, Torikai, H.1, Kellar, D.1,
Gibbons, H.1, Hernandez, J.2, Andersson, H.1, Huls, H.1, Lee, D.1,
Hwu, P.2, Radvanyi, L.2, Cooper, L.1 1M.D. Anderson Cancer Center,
Houston, TX; 2M.D. Anderson Cancer Center, Houston, TX
Measurement and skewing ofT-cell receptor (TCR)a and b diver-
sity in the tumor-bearing host (i) engrafted with allogeneic hemato-
poietic stem cells and/or (ii) after vaccination or adoptive T-cell
transfer, are used for monitoring the effect of immunotherapies.
TCR diversity is mostly concentrated within the third complemen-
tarity-determining region (CDR3) of a and b chains. Currently avail-
able methods for measuring diversity are primarily limited to
TCRVb usage and are (i) flow-cytometric detection by using
